European Commission publishes the first Joint Clinical Assessment report

The European Commission has published the first joint clinical assessment (JCA) report under the Health Technology Assessment (HTA) Regulation, marking a major milestone in strengthening cooperation on the assessment of innovative medicines across the EU.

It assesses the relative effectiveness and relative safety of Ojemda (tovorafenib), an orphan medicine to treat paediatric low-grade glioma - the most common type of brain tumour in children.

In addition, two new EU-HTA procedures were initiated: cosibelimab for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), and the ATMP drug lunsotogene parves for the treatment of biallelic OTOF variant-associated hearing loss in adults and children.